Mélinda Charrier

Association of the Lung Immune Prognostic Index With Immune Checkpoint Inhibitor Outcomes in Patients With Advanced Non–Small Cell Lung Cancer

Laura Mezquita, Édouard Auclin, Roberto Ferrara et al. · JAMA Oncology · 2018 · 925 citations · Full text

Dendritic cell-derived exosomes as maintenance immunotherapy after first line chemotherapy in NSCLC

Benjamin Besse, Mélinda Charrier, Valérie Lapierre et al. · OncoImmunology · 2015 · 754 citations · Full text

Immunology, Immunotherapeutics, Immunotherapy +20

Colon Immune-Related Adverse Events: Anti-CTLA-4 and Anti-PD-1 Blockade Induce Distinct Immunopathological Entities

Clélia Coutzac, Julien Adam, Émilie Soularue et al. · Journal of Crohn s and Colitis · 2017 · 161 citations

Predicting immunotherapy outcomes under therapy in patients with advanced NSCLC using dNLR and its early dynamics

Laura Mezquita, Isabel R. Preeshagul, Édouard Auclin et al. · European Journal of Cancer · 2021 · 56 citations · Full text

Advanced Nsclc, Early Dynamics, Disease Progression +9

Circulating innate immune markers and outcomes in treatment-naïve advanced non–small cell lung cancer patients

Mélinda Charrier, Laura Mezquita, B. Lueza et al. · European Journal of Cancer · 2019 · 46 citations · Full text

Prognostic Biomarkers, Cancer Immunosurveillance, Lung Inflammation +11